Strategies for the use of nonstatin therapies

Area of Science:

• Cardiology
• Pharmacology
• Lipidology

Background:

• Dyslipidemias, particularly high low-density lipoprotein cholesterol (LDL-C), are significant risk factors for cardiovascular disease (CVD).
• Statins are primary treatments, but many patients have suboptimal responses or side effects, necessitating alternative strategies.
• Residual cardiovascular risk persists in some patients due to other lipid abnormalities like elevated triglycerides or low high-density lipoprotein cholesterol (HDL-C).

Purpose of the Study:

• To review current therapeutic options for managing dyslipidemias beyond standard statin therapy.
• To highlight the efficacy of combination therapies and novel agents in achieving lipid goals.
• To provide guidance for patients with statin intolerance or residual risk.

Main Methods:

• Review of recent clinical studies and therapeutic guidelines.
• Analysis of data on lipid-lowering drug efficacy and safety.
• Evaluation of treatment strategies for statin-intolerant patients and those with complex lipid profiles.

Main Results:

• Combination therapy with ezetimibe and statins (rosuvastatin or atorvastatin) enhances lipid reduction.
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors demonstrate significant LDL-C lowering and cardiovascular event reduction.
• Alternative agents provide viable options for patients not achieving targets or experiencing statin intolerance.

Conclusions:

• A range of pharmacological options exist for patients with dyslipidemia who are statin-intolerant or have residual risk.
• Combination therapies and newer agents like PCSK9 inhibitors are crucial for optimizing cardiovascular risk management.
• Treatment individualization is key, utilizing monotherapy or add-on therapy with maximally tolerated statin doses.